Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC

Published:2024-06 Issue:6 Volume:27 Page:110132
ISSN:2589-0042
Container-title:iScience
language:en
Short-container-title:iScience

Author:

Mirzapoiazova Tamara,Tseng Liz,Mambetsariev Bolot,Li Haiqing,Lou Chih-Hong,Pozhitkov Alex,Ramisetty Sravani Keerthi,Nam Sangkil,Mambetsariev Isa,Armstrong Brian,Malhotra Jyoti,Arvanitis Leonidas,Nasser Mohd Wasim,Batra Surinder K.,Rosen Steven T.,Wheeler Deric L.,Singhal Sharad S.,Kulkarni Prakash,Salgia Ravi^ORCID

Funder

U.S. Department of Defense

National Institutes of Health

NCI

Publisher

Elsevier BV

Reference50 articles.

1. Small cell lung cancer (SCLC): no treatment advances in recent years;Koinis;Transl. Lung Cancer Res.,2016

2. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline;Rudin;J. Clin. Onco.,2015

3. Cancer Facts & Figures 2015;Society,2015

4. Small cell lung cancer from traditional to innovative therapeutics: building a comprehensive network to optimize clinical and translational research;Subbiah;J. Clin. Med.,2020

5. The role of mitochondrial dynamics in human cancers;Ma;Am. J. Cancer Res.,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP